Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Diffuse Large B Cell Lymphoma (DLBCL): early-phase trial registry
1 of 3 indexed Refractory Diffuse Large B Cell Lymphoma (DLBCL) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Refractory Diffuse Large B Cell Lymphoma (DLBCL): 3 US clinical trials tracked, 1 recruiting.
Refractory Diffuse Large B Cell Lymphoma (DLBCL) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Miltenyi Biomedicine, running 1 of these trials.
Enrollment posture brief
Registry condition refractory-diffuse-large-b-cell-lymphoma-dlbcl
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Refractory Diffuse Large B Cell Lymphoma (DLBCL) lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Diffuse Large B Cell Lymphoma (DLBCL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Diffuse Large B Cell Lymphoma (DLBCL) is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine
NCT04792489
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center
NCT02570542
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
Kite, A Gilead Company
NCT02348216
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Diffuse Large B Cell Lymphoma (DLBCL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Diffuse Large B Cell Lymphoma (DLBCL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Diffuse Large B Cell Lymphoma (DLBCL) page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Refractory Diffuse Large B Cell Lymphoma (DLBCL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Miltenyi Biomedicine sponsors the most Refractory Diffuse Large B Cell Lymphoma (DLBCL) trials on record, review their full trial history before evaluating a specific study. See Miltenyi Biomedicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Diffuse Large B Cell Lymphoma (DLBCL) condition card totals 3 registered trials; most-linked intervention Fludarabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.